The available literature does not provide any questionnaire to evaluate sexual function after male to female (MtF) gender reassignment surgery (GRS). The assessment of sexual function in these patients is routinely performed by using tools designed for biological women, such as Female Sexual Function Index (FSFI). Such a limit leads to a suboptimal evaluation, especially in domains like lubrication and dyspareunia. Moreover, FSFI scores in MtF patients often are similar to those observed in nontranssexual women with sexual dysfunction. We aim at developing validate new questionnaire, the operated Male to Female Sexual Function Index (oMtFSFI) in order to assess sexual function in patients who underwent MtF GRS.
INTRODUCTION AND OBJECTIVES:
The available literature does not provide any questionnaire to evaluate sexual function after male to female (MtF) gender reassignment surgery (GRS). The assessment of sexual function in these patients is routinely performed by using tools designed for biological women, such as Female Sexual Function Index (FSFI). Such a limit leads to a suboptimal evaluation, especially in domains like lubrication and dyspareunia. Moreover, FSFI scores in MtF patients often are similar to those observed in nontranssexual women with sexual dysfunction. We aim at developing validate new questionnaire, the operated Male to Female Sexual Function Index (oMtFSFI) in order to assess sexual function in patients who underwent MtF GRS.
METHODS: A panel of experts in gender dysphoria defined salient content areas to be explored. Ten MtF patients were administered the questionnaire in order to check its face validity. Their suggestions helped the expert revising the initial version. The revised oMtFSFI questionnaire presents 18 items and was applied in the present study. oMtFSFI with FSFI, Back Depression Inventory II and SF-36 questionnaires were web-based administered to 125 operated MtF patients, recruited during follow-up visits in 7 italian centres and to 80 women who provided self-ratings. The MtF participants completed oMtFSFI twice, three to four weeks apart.
RESULTS: 65 MtF and 57 women completed the study. The two groups did not differ in their age (mean 38.5 SD 9.3 versus 37.7 SD 11.5 years old) or in their present vs not sexual activity in the last month (p[0.18). MtFs underwent GRS up to 19 years before (mean 5.1). Principal component analysis performed on the self-ratings provided by MtFs yielded a 3-domain structure (accounting for the 68.7% of the total variance): Sexual Dissatisfaction, Sexual Pain and Genital self-image. The same structure emerged when data from the whole group were analysed. For MtFs, Cronbach Alphas ranged from 0.64 to 0.93 for the three domains. After controlling for age and years from surgery, clear convergent associations with FSFI scales were found for Sexual Dissatisfaction and Sexual Pain but not for Genital Self-image; BDI did not account for additional variance.
CONCLUSIONS: These results support the reliability and psychometric validity of the oMtFSFI in the assessment of key dimensions of transsexual women sexual function. Further studies are needed to develop a diagnostic cut-off scores for a potential classification of operated MtF's sexual dysfunction.
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MP40-04 PREVALENCE OF TESTOSTERONE DEFICIENCY IN MEN AGED OVER 80 YEARS IS NOT INCREASED IN NONOBESE INDIVIDUALS
Taciana Tiraboschi, Monique Caires, Eduardo P Miranda*, Caroline Silva, Mateus Alvaia, Ueslei Menezes, Leopoldo Neto, Jose Murillo Bastos Netto, Cristiano M Gomes, Jose Bessa Jr, Feira de Santana, Brazil INTRODUCTION AND OBJECTIVES: Epidemiological studies have demonstrated that testosterone production has a steady decline over the years. However, there have been conflicting reports assessing different patient populations in which age has not been an independent predictor of testosterone deficiency (TD). The aim of this study was to compare the prevalence of TD in a cohort of men over 80 years of age in comparison to middle-aged men and identify predictors for such condition.
METHODS: Two different cohorts of patients seen at our institution from 2012 to 2018 were compared: i) patients aged >80 years seen at the geriatric center of our institution for routine follow-up (group 80þ); ii) men aged 40 to 75 years who were evaluated at a prostate cancer-screening program (group 40-75). TD was defined as T levels <300ng/dl. Clinical and demographic data were obtained from medical records. Groups were compared regarding the presence of TD and metabolic syndrome (MS) components. MetS were considered present when 3 or more of the following were identified: the presence of hypertension, increased waist circumference (WC >102 cm), elevated blood glucose level (>100 ng/dl) and abnormal serum lipid profile (HDL < 40 mg/dL and triglycerides > 150 mg/dL).
RESULTS: 197 subjects were included in group 80þ with a mean age (AESD) of 83AE4 years (range 80-97 years), and group 40-75 had 2562 men with mean age of 56AE9 years (range 40-74 years). The prevalence of TD was similar between groups: mean T (AESEM) was: 458AE15 ng/dL in group 80þ and 410AE8 ng/dL in group 40-75, p[0.12. The prevalence of MetS (group 80þ 28% vs. group 40-75 32%) and the number MetS components were also similar between groups (p>0.05), except for the fact that group 80þ had a higher prevalence of hypertension (73% vs. 43%, p[<0.0001) and group 40-75 had more individuals with obesity (34% vs. 21%, p[0.0001). Elevated waist circumference was the most important predictor for TD in elderly individuals, as those in the highest quartile for WC (>102 cm) were ten times more likely to have TD than those in the lowest quartile (WC<90 cm, OR[10.2, 95%CI 2.8-34.3, p<0.0001).
CONCLUSIONS:: In our study, no significant difference was noted between T levels in octogenarians and middle-aged men. For individuals with WC<102 cm, age appears not to have a significant impact on T levels.
Source of Funding: None
MP40-05 DIAGNOSIS AND MANAGEMENT OF TESTOSTERONE DEFICIENCY -COMPARISON OF CURRENT GUIDELINES
Jethro C.C. Kwong*, Yonah Krakowsky, Ethan Grober, Toronto, Canada INTRODUCTION AND OBJECTIVES: Testosterone deficiency (TD) is characterized by low levels of testosterone (T) with associated signs and symptoms. Several controversies related to approach to TD have been identified. We compare current guidelines for the diagnosis and management of TD, as well as special considerations for specific patient populations.
METHODS: The following guidelines were included for analysis: American Urological Association (AUA, 2018), European Association of Urology (EAU, 2018), Endocrine Society (ES, 2018), and Canadian Medical Association (CMAJ, 2015) . The comparison focused on the biochemical definition (cut-off) for low T, principles of management of TD, and recommendations for patients with low-to-normal total testosterone, prostate cancer, or cardiovascular disease.
RESULTS: Recommendations are generally consistent across guidelines, however there are notable differences (Table 1) . For biochemical cut-off, most guidelines require 2 lab measurements of total T ranging between 8 to 10.4 nmol/L, however the CMAJ requires only one measurement and has no specific cut-off. In patients with low-tonormal total T, additional hormonal evaluation is recommended, however only the CMAJ suggests a 3-month trial of TTh in symptomatic patients. The ES has the strictest recommendations for patients with TD and prostate cancer. Other guidelines generally recommend against TTh in patients with metastatic prostate cancer. Although there is limited evidence linking TTh and risk of cardiovascular events (MI, stroke, sudden CV death), the AUA and
